< Back to previous page
Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 63
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gut functional and inflammatory disorders: biomarker and therapeutic target discovery (GUT-FIRE)From10 Jul 2023 → TodayFunding: IOF - mandates
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom1 Apr 2023 → TodayFunding: HORIZON.2.1 - Health
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Feb 2023 → TodayFunding: BOF - projects
- Characterization of triggers of post-operative recurrence in Crohn’s disease in both the external and luminal side of the intestineFrom1 Jan 2023 → TodayFunding: FWO research project
- Development of a gut-on-a-chip model for pre-clinical testing of drugs for inflammatory bowel diseaseFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Jun 2022 → TodayFunding: BOF - various
- Host-microbe interaction in intestinal homeostasis: unravelling the mechanisms involved in the onset of multiple inflammationrelated diseasesFrom1 Jan 2022 → TodayFunding: FWO EOS
- Histological healing in inflammatory bowel diseaseFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
11 - 20 of 1016
- A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.(2024)
Authors: Séverine Vermeire
Pages: S2468-1253 - Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial(2024)
Authors: Séverine Vermeire
- Upgrading therapeutic ambitions and treatment outcomes(2024)
Authors: Séverine Vermeire
Pages: 84 - 85 - Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis(2024)
Authors: Séverine Vermeire
Pages: 393 - 408 - Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.(2024)
Authors: Séverine Vermeire
Pages: 54 - 64 - Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial(2024)
Authors: Séverine Vermeire
- Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study(2024)
Authors: Dahham Alsoud, João Guedelha Sabino, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
- Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST(2024)
Authors: Séverine Vermeire
Pages: 175 - 185 - Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study(2024)
Authors: Jo Swinnen, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
- The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis(2024)
Authors: Matthias Lenfant, Bram Verstockt, João Guedelha Sabino, Séverine Vermeire, Marc Ferrante
Pages: 1 - 7
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)